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Influence of mycophenolic acid and tacrolimus on homocys- duces the proliferation of smooth muscle cells. However,
teine metabolism. the majority of studies used supraphysiological concen-
Background. The effect of mycophenolate mofetil (MMF) trations of homocysteine [1].on homocysteine (Hcy) metabolism is unknown.
In stable kidney graft recipients, hyperhomocysteine-Methods. This in vitro study examined whether mycophe-
nolic acid or tacrolimus influences the formation of Hcy as mia [total homocysteine (tHcy) plasma concentrations
determined by measuring the total Hcy (tHcy) concentrations 15 mol/L] is present in approximately 50 to 60% of
in supernatants of human renal proximal tubule epithelial cells. the patients [2, 3]. Total homocysteine plasma concentra-Cells were incubated with and without vitamins (folate, vitamin
tion correlates inversely with the glomerular filtrationB6 and B12) in the presence of low or high methionine concen-
trations at different mycophenolic acid (0, or 5, or 20 g/mL) rate, and is roughly three times as high in hemodialysis
or tacrolimus (0, or 10, or 25 ng/mL) concentrations for 24, 48 patients as compared to healthy individuals. Therefore,
or 72 hours. The concentration of tHcy in culture supernatants tHcy would be expected to fall markedly after successfulwas measured by a fluorescence polarization immunoassay.
renal transplantation. Thus far, no study has explainedThe effect of MMF on tHcy plasma levels was also examined
in 454 kidney graft recipients. why the post-transplant reduction in tHcy is far smaller
Results. Comparisons of tHcy levels in culture supernatants than expected with respect to improved renal function
over time by four way ANOVA showed that methionine con- [4]. One potential explanation for this observation iscentration (P  0.00001), time (P  0.00001), vitamins (P 
the influence of the immunosuppressive therapy on Hcy0.002728), and mycophenolic acid concentration (P 
0.000095) were all significant predictors of tHcy concentrations. metabolism in transplant patients. Some authors reported
This was due to significantly lower tHcy levels with using myco- an association of cyclosporine A therapy with elevated
phenolic acid at a high concentration versus control at the 48-
tHcy levels in kidney or heart allograft recipients [4–7].and 72-hour time points. By contrast, tacrolimus showed no
This finding, however, has not been confirmed by oureffect in vitro. Among the kidney graft recipients, male patients
on MMF therapy showed lower plasma tHcy concentrations prior studies where cyclosporine A did not have any ef-
as compared to those on azathioprine (P  0.03). fect on Hcy metabolism in vitro or in vivo (abstract;
Conclusion. Our study suggests a tHcy lowering effect of
Sunder-Plassmann G, J Am Soc Nephrol 11:726A, 2000)MMF in male transplant recipients, which improves the cardio-
[8]. It has been shown recently that patients on a triplevascular disease risk profile, whereas tacrolimus showed no
effect. therapy with steroids, tacrolimus, and mycophenolate mo-
fetil show lower tHcy values than those on double therapy
with cyclosporine A and prednisolone or tacrolimus and
Hyperhomocysteinemia shows an association with vas- prednisolone (abstract; Scolari MP, XVIII International
cular disease [1]. Experimental studies have shown that
Congress of the Transplantation Society, 2000, p 323).homocysteine may exert harmful effects on endothelial
These data suggest that mycophenolate mofetil inter-cells. It interferes with several clotting factors, increases
feres with homocysteine metabolism. Therefore, the aimplatelet aggregation, enhances lipid oxidation, and in-
of our study was to assess whether mycophenolic acid,
the active metabolite of mycophenolate mofetil, may
Key words: kidney transplantation, vascular disease, hyperhomocys-
play a role in the metabolism of Hcy. Human renal proxi-teinemia, mycophenolate mofetil, renal proximal tubule epithelial cells,
methionine, folate, vitamin B6, vitamin B12. mal tubule epithelial cells (huRPTEC), an important
metabolic site of Hcy, were used to test this hypothesis,Received for publication August 3, 2001
and the results were compared to tacrolimus. The effectand in revised form November 27, 2001
Accepted for publication December 17, 2001 of mycophenolate mofetil on tHcy plasma concentra-
tions also was examined in 454 kidney graft recipients. 2002 by the International Society of Nephrology
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METHODS 4.3 kg/m2; mean time since transplantation, 3.8  3.2
years; mean serum creatinine concentration, 1.8  1.1Cell culture
mg/dL). The estimated creatinine clearance was 54.4 
Human renal proximal tubule epithelial cells (huRP-
19.9 mL/min, the mean folate plasma level was 14.7 TEC; provided by BioWhittaker-Clonetics, Walkersville,
11.0 nmol/L, and the mean vitamin B12 plasma level wasMD, USA) were obtained in the second passage and
242  129 pmol/L. These patients had participated in asubcultured according to the manufacturer’s specifica-
previous study investigating the genetic background oftions, in renal epithelial cell basal medium enriched with
hyperhomocysteinemia of renal transplant patients [10].growth factors (REGM singlequots; BioWhittaker-Clo-
The cross sectional study design included two groups:netics). After cryopreservation in the fifth passage, cells
The first group (N 326) consisted of patients on a triplewere thawed and seeded in 175 cm2 cell culture flasks in
therapy (cyclosporine A, prednisone and azathioprine),Dulbecco’s modified Eagle medium (DMEM) contain-
and the second group of 128 patients received a tripleing 10% fetal calf serum (FCS) and 5 mL of penicillin-
drug regimen using cyclosporine A, prednisone, and my-streptomycin solution (10,000 IE penicillin  10,000 g
cophenolate mofetil. All patients gave written informedstreptomycin/mL).
consent for this study according to the Declaration ofEighty percent confluent cells were then subcultured
Helsinki and the Austrian Law on Gene Technology.in six-well plates using RPMI 1640 medium supple-
For the analysis of tHcy plasma concentration of pa-mented with 5% FCS, 5 mL of penicillin-streptomycin,
tients (normal, 15 mol/L), citrated blood was drawn2 mL of fungizone (250g/mL Amphotericin B), 5 mL of
after an overnight fast in chilled tubes and spun withinl-glutamine (29.2 mg/mL), 500L of gentamycin (50 mg/
20 minutes at 4C at 2000 	 g. Platelet poor plasma wasmL) and 2500 IE of heparin (Immuno, Vienna, Austria).
stored at
70C. The concentration of tHcy in the plasmaOne set of cells was incubated with vitamin B12 (0.005
samples was determined by HPLC as described by Arakimg/L), folic acid (1 mg/L) and pyridoxal-HCl (1 mg/L),
and Sako [9].and one set without these vitamins. These sets were
incubated in the presence of a methionine concentration Statistics
of 15 mg/L or 150 mg/L and with different concentrations
Continuous data are given as mean  SD. Compari-of mycophenolic acid (0g/mL, or 5g/mL, or 20g/mL;
sons of tHcy levels in culture supernatants over timeF. Hoffmann-La Roche AG, Basel, Switzerland), or ta-
were performed by four way ANOVA comparing myco-crolimus (0 ng/mL, or 10 ng/mL, or 25 ng/mL; Fujisawa
phenolic acid (0, or 5, or 20 g/mL) or tacrolimus (0, orIreland Ltd., Killorglin, Co. Kerry, Ireland), respectively.
10, or 25 ng/mL), methionine (low or high), vitaminsAll sets were incubated for either 24, 48 or 72 hours.
(yes or no), time of incubation (24, 48 or 72 hours), andA total number of six experiments were performed
the interaction terms for the aforementioned factors. Ausing one cell batch. The viability of the cells was deter-
three way ANOVA was performed for all measurementsmined using the trypan blue method and was found to
for the time points 24, 48, and 72 hours with the factorsbe 95%. The cell culture reagents used were obtained
mycophenolic acid or tacrolimus, methionine and vita-from Life Technologies (Vienna, Austria) unless other-
mins; t tests were used to compare tHcy plasma levels ofwise indicated.
the users of mycophenolate mofetil versus azathioprine.
Measurement of total homocysteine in A multiple regression model was built to identify inde-
cell supernatants pendent predictors of tHcy plasma levels. Variables in-
cluded in this model were age, time since transplantation,The concentration of tHcy in the supernatants was
body mass index, serum creatinine, glomerular filtrationdetermined in duplicates using a fluorescence polariza-
rate, gender, primary kidney disease, folate levels, B12tion immunoassay (IMx analyzer; Abbott Laboratories,
concentration, MTHFR 677/1298 genotypes, and the my-Abbott Park, IL, USA). The lower detection limit of the
cophenolate mofetil use yes/no term. Skewed data wereassay was 0.5 mol/L. The IMx assay revealed compara-
transformed logarithmically to normalize the distribution.ble results for tHcy concentrations as compared to the
A P value of0.05 was considered statistically signifi-values obtained by high performance liquid chromatog-
cant. All calculations were performed using Statistica forraphy (HPLC) [9]. The detailed comparison of both
Windows (release 4.5, Stat Soft Inc., 1993).methods for measurement of tHcy in cell culture super-
natants will be reported elsewhere.
RESULTSPatient characteristics
Influence of mycophenolic acid on homocysteineThe influence of mycophenolate mofetil on tHcy levels
export from huRPTECof kidney graft recipients was investigated in 454 patients.
The mean tHcy concentration in the culture super-The mean age of the 185 female and 269 male patients
was 50.7  13.3 years (mean body mass index, 25.6  natants was 3.51  0.27 mol/L under standard cell cul-
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Table 2. Tacrolimus does not influence tHcy concentrationsTable 1. Mycophenolic acid decreases tHcy concentrations
in culture supernatants of huRPTEC in culture supernatants of huRPTEC
tHcy lmol/LtHcy lmol/L
MPA Met Tacrolimus Met
ng/mL Vitamins mg/L 24 h 48 h 72 hlg/L Vitamins mg/L 24 h 48 h 72 h
0 wo 15 3.700.57 5.800.66 6.750.75 0 wo 15 2.050.88 2.890.74 3.520.78
0 w 15 2.080.80 3.130.86 3.650.760 w 15 3.510.27 5.120.34 5.710.45
0 wo 150 4.910.64 7.531.29 9.691.34 0 wo 150 4.081.64 5.981.59 7.291.43
0 w 150 4.401.46 6.841.68 8.281.250 w 150 4.640.87 7.260.88 11.112.61
5 wo 15 3.700.43 5.280.28 6.861.17 10 wo 15 1.970.96 3.030.96 3.420.85
10 w 15 2.060.93 3.080.81 3.540.805 w 15 3.500.62 4.620.45 5.230.32
5 wo 150 4.890.85 7.281.05 9.040.95 10 wo 150 4.121.26 6.001.14 7.911.63
10 w 150 4.411.50 6.381.43 7.951.835 w 150 4.050.31 6.600.85 8.681.18
20 wo 15 3.650.80 5.040.39 5.700.40 25 wo 15 2.150.87 3.120.80 3.580.87
25 w 15 2.230.83 3.200.69 3.800.7720 w 15 3.310.51 4.510.31 5.010.23
20 wo 150 4.710.83 6.460.44 8.781.19 25 wo 150 4.191.27 6.231.03 7.450.87
25 w 150 4.271.62 6.661.64 7.831.5920 w 150 4.000.26 6.300.82 8.641.49
Data are mean  SD. Abbreviations are: Met, methionine; tHcy, total homo-Data are mean  SD. Abbreviations are: MPA, mycophenolic acid; Met,
methionine; tHcy, total homocysteine; w, with vitamins; wo, without vitamins. cysteine; w, with vitamins; wo, without vitamins.
Influence of tacrolimus on homocysteine export
from huRPTEC
The mean tHcy concentration in the cell culture super-
natants was 2.08 0.8mol/L under standard cell culture
conditions at the 24-hour time point and increased to
3.13  0.86 mol/L (50.48%) at 48 hours and to 3.65 
0.76 mol/L (75.48%) at 72 hours (Table 2). Compari-
sons of tHcy concentrations in cell culture supernatants
over time by four way ANOVA showed that methionine
loading (P  0.000001) and prolonged incubation time
(P  0.000001) were associated with an increase in tHcy
export from huRPTEC. The presence of tacrolimus in
the medium did not influence Hcy export (P  0.9733)
as compared to standard cell culture conditions. Separate
analyses of the three different time points by three way
ANOVA did not show an influence of tacrolimus for
Fig. 1. Export of homocysteine (Hcy) from human renal proximal tu- any of the concentrations used.bular epithelial cells (huRPTEC) in the presence of 20g/mL mycophe-
nolic acid ( ) and under control conditions () with and without
Mycophenolate mofetil use and tHcy plasmamethionine loading and in the presence or absence of vitamins (at 48
hours). Data are mean  SD. Abbreviations are: tHcy, total homocys- concentration in renal transplant patients
teine concentration; Met, methionine; Vit , with vitamins B6, B12 and
The mean tHcy plasma concentration among the en-folic acid; Vit 
, without vitamins B6, B12 and folic acid.
tire study population (N  454) was 18.2  9.6 mol/L.
The mean tHcy plasma level among users of mycopheno-
late mofetil versus users of azathioprine was 17.5 
10.0 mol/L and 18.5  9.5 mol/L, respectively. Thisture conditions at time point 24 hours, and increased by
was related to significantly lower tHcy plasma levels in
45.86% at 48 hours and 62.67% at 72 hours (Table 1).
male patients treated with mycophenolate mofetil versus
Comparisons of tHcy levels in culture supernatants over male patients treated with azathioprine (P  0.030). In
time by four way ANOVA showed that in vitro methio- the female population there was no difference between
nine loading (P  0.000001) and prolonged incubation the users of azathioprine versus mycophenolate mofetil
time (P  0.000001) were associated with an increase of (Table 3). The independent predictors of tHcy levels are
tHcy export from huRPTEC, whereas the presence of indicated in Table 4.
vitamins (P  0.002728) and mycophenolic acid (P 
0.000095) was associated with a significant decrease in
DISCUSSIONtHcy export. Separate analyses of the three different time
points by three way ANOVA showed that mycophenolic Our study shows that mycophenolic acid reduces homo-
acid significantly reduced tHcy export from huRPTEC cysteine export from human renal proximal tubule epi-
at 48 and 72 hours (P  0.000599 and P  0.0001523, thelial cells. By contrast, tacrolimus did not have any ef-
fect on Hcy metabolism in vitro. Among 454 kidney graftrespectively; Fig. 1).
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Table 4. Multiple regression analysis of predictors of tHcyTable 3. Gender specific differences in tHcy plasma concentrations
using mycophenolate mofetil versus azathioprine plasma concentrations in 454 renal graft recipients
Parameter PGender MMF AZA P
Male 17.51 19.87 0.030 Age 0.734
Gender 0.623N69 N200
Female 17.54 16.19 0.422 Body mass index 0.540
Time since transplantation 0.472N59 N126
Both 17.52 18.45 0.159 Body mass index 0.540
Primary kidney disease 0.881Abbreviations are: MMF, mycophenolate mofetil; AZA, azathioprine.
Serum creatinine concentration 0.052
Creatinine clearance 0.118
Plasma folate concentration 0.000377
Plasma vitamin B12 concentration 0.00048recipients, the use of mycophenolate mofetil was associ- MTHFR 677/1298 genotypes 0.032
Use of mycophenolate mofetil 0.493ated with lower tHcy plasma levels in male patients.
There is good evidence that normal kidneys play a
major role in amino acid and Hcy clearance and metabo-
lism. The existence of Hcy-metabolizing enzymes and Another point of concern is the mechanism by which
uptake systems in renal tubular cells has been confirmed mycophenolate mofetil influences Hcy metabolism. My-
[11]. We used renal proximal tubule epithelial cells be- cophenolic acid is the active metabolite of mycopheno-
cause urinary folate excretion is regulated by the degree late mofetil and inhibits the enzyme inosine 5-mono-
of reabsorption of folate by the proximal tubule cells phosphate dehydrogenase [18]. This enzyme plays a key
role in purine nucleotide biosynthesis, which is crucialand thus is important in the metabolism of homocysteine
for cell proliferation. The effect on lymphocyte prolifera-[12]. In addition to reabsorbing folate from the tubular
tion is more pronounced because other cells are capablelumen, the proximal tubule cells secrete folate in vivo
of using an alternate pathway for guanosine synthesis.[13]. In culture, proximal tubule cells have been shown
Taken together, the effect of mycophenolic acid on tHcyto possess folate transport pathways [14] and to main-
plasma concentrations may be related, at least in part,tain domain-specific nutrient transport across the epithe-
to a decrease in protein turnover that is due to inhibitionlium [15]. Homocysteine is an endogenous sulfur-con-
of cell proliferation.taining amino acid intermediate of the essential amino
Previous studies demonstrated that creatinine clear-acid methionine and is not obtained from the diet. The
ance, folate status, and MTHFR 677TT genotype aremetabolism of homocysteine is at the junction of two
the most important predictors of tHcy plasma levels inmetabolic pathways: remethylation and transsulfuration.
kidney graft recipients [3]. The prevalence of hyperho-In remethylation, homocysteine acquires a methyl group
mocysteinemia is high even in allograft recipients withfrom 5-methyltetrahydrofolate (MTHF) or from betaine
normal renal function. One explanation for this observa-to form methionine. The reaction with MTHF occurs in
tion is the potential influence of the immunosuppressiveall tissues and is vitamin B12-dependent, while the reac- therapy on Hcy metabolism. Arnadottir et al were the
tion with betaine is confined to the liver (and kidneys,
first to suggest that cyclosporine A use, via a yet undefined
in humans) and is vitamin B12-independent [16]. Renal mechanism, may be associated with higher tHcy plasma
proximal cells take up MTHF by both the folate receptor levels in kidney graft recipients [4, 5]. This association,
and the reduced folate carrier, implying a role for both however, was not confirmed in vitro [8] or in vivo (abstract;
pathways in regulating urinary folate excretion and Sunder-Plassmann et al, J Am Soc Nephrol 11:726A,
homocysteine metabolism [12]. 2000). Of note, this US-Austrian study is the largest study
The more pronounced effect of mycophenolic acid on on renal transplant recipients and immunosuppressive
Hcy metabolism in vitro than in vivo deserves attention. therapy to date. The present study shows that mycophe-
This difference may be explained by the constant and nolic acid may have some tHcy plasma concentration-
rather high concentration of mycophenolic acid used in lowering effect in male kidney graft recipients. The most
the cell culture medium. Patients treated with mycophe- important determinants of tHcy plasma concentrations,
nolate mofetil normally receive a dose of 1 g twice daily. however, remain the serum folate and vitamin B12 con-
Looking at the pharmacokinetic of the drug, the peak centrations.
plasma concentration of the active metabolite mycophe- Following heart transplantation, an increase of tHcy
nolic acid occurs roughly after two hours following inges- plasma levels also has been observed [19]. Cole et al
tion. Investigation of the concentration-time profiles re- examined the effect of several variables on tHcy plasma
vealed that Cmax was in the range of 15 to 20 g/mL for concentrations in 72 heart transplant recipients. In a mul-
mycophenolic acid and concentrations were2.5 g/mL tiple linear regression model, only creatinine and trough
cyclosporine A concentrations were independent posi-within 12 hours after administration [17].
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cago, and at the 2001 annual meeting of the European Dialysis andtive predictors of tHcy [6]. Comparable results also were
Transplantation Association (EDTA) in Vienna.
obtained in the study of Cook et al [7]. By contrast,
azathioprine showed no influence on tHcy plasma levels Reprint requests to Mihaela Cristiana Ignatescu, M.D., Klinische
Abteilung fu¨r Nephrologie und Dialyse Universita¨tsklinik fu¨r Innerein renal transplant patients [2].
Medizin III, Wa¨hringer Gu¨rtel 18-20, A-1090 Wien, Austria.In the present study, the export of Hcy by human E-mail: michaela.ignatescu@nephro.imed3.akh-wien.ac.at
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